Detalles de la búsqueda
1.
Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus.
Br J Clin Pharmacol
; 90(2): 606-612, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37897064
2.
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes.
Diabetes Obes Metab
; 23(4): 991-1000, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33368935
3.
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.
Diabetes Obes Metab
; 23(5): 1101-1110, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33394543
4.
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
J Pharmacol Exp Ther
; 375(1): 76-91, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32764153
5.
Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
Diabetes Obes Metab
; 22(12): 2493-2498, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32803900
6.
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
Diabetes Obes Metab
; 22(5): 798-806, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31912603
7.
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Cardiovasc Diabetol
; 18(1): 138, 2019 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31640705
8.
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.
Diabetes Obes Metab
; 21(4): 829-836, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30456904
9.
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Diabetes Obes Metab
; 21(12): 2684-2693, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31423699
10.
Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
Diabetes Obes Metab
; 20(8): 2034-2038, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29663628
11.
Novel orally swallowable IntelliCap(®) device to quantify regional drug absorption in human GI tract using diltiazem as model drug.
AAPS PharmSciTech
; 15(6): 1490-7, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25023947
12.
Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate.
Clin Pharmacokinet
; 63(4): 551-560, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38504082
13.
Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model-informed drug development case study.
CPT Pharmacometrics Syst Pharmacol
; 13(2): 296-307, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38050337
14.
Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus.
J Clin Pharmacol
; 63(5): 551-559, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36543754
15.
Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model.
Front Pharmacol
; 14: 1229255, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37954838
16.
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes.
CPT Pharmacometrics Syst Pharmacol
; 12(6): 831-841, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36912425
17.
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
J Clin Pharmacol
; 62(10): 1227-1235, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35403243
18.
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis.
J Clin Pharmacol
; 62(4): 541-554, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34657303
19.
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
J Clin Pharmacol
; 61(5): 636-648, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33091173
20.
Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
CPT Pharmacometrics Syst Pharmacol
; 9(4): 222-229, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32064793